» Articles » PMID: 28732212

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2017 Jul 22
PMID 28732212
Citations 3233
Authors
Affiliations
Soon will be listed here.
Abstract

Genomics data from The Cancer Genome Atlas (TCGA) project has led to the comprehensive molecular characterization of multiple cancer types. The large sample numbers in TCGA offer an excellent opportunity to address questions associated with tumo heterogeneity. Exploration of the data by cancer researchers and clinicians is imperative to unearth novel therapeutic/diagnostic biomarkers. Various computational tools have been developed to aid researchers in carrying out specific TCGA data analyses; however there is need for resources to facilitate the study of gene expression variations and survival associations across tumors. Here, we report UALCAN, an easy to use, interactive web-portal to perform to in-depth analyses of TCGA gene expression data. UALCAN uses TCGA level 3 RNA-seq and clinical data from 31 cancer types. The portal's user-friendly features allow to perform: 1) analyze relative expression of a query gene(s) across tumor and normal samples, as well as in various tumor sub-groups based on individual cancer stages, tumor grade, race, body weight or other clinicopathologic features, 2) estimate the effect of gene expression level and clinicopathologic features on patient survival; and 3) identify the top over- and under-expressed (up and down-regulated) genes in individual cancer types. This resource serves as a platform for in silico validation of target genes and for identifying tumor sub-group specific candidate biomarkers. Thus, UALCAN web-portal could be extremely helpful in accelerating cancer research. UALCAN is publicly available at http://ualcan.path.uab.edu.

Citing Articles

Pan-cancer bioinformatics analysis of TIPRL in human tumors.

Zhang X, Xue H, Lv Y, Zhou Y, Sha K, Liu T Discov Oncol. 2025; 16(1):320.

PMID: 40088344 DOI: 10.1007/s12672-025-02070-9.


A Truncated Mutation of TP53 Promotes Chemoresistance in Tongue Squamous Cell Carcinoma.

Du X, Zheng J, Lu X, Zhang Y Int J Mol Sci. 2025; 26(5).

PMID: 40076972 PMC: 11900931. DOI: 10.3390/ijms26052353.


EXO1's pan-cancer roles: diagnostic, prognostic, and immunological analyses through bioinformatics.

Liu Z, Huang S, Luo R, Shi X, Xiu M, Wang Y Discov Oncol. 2025; 16(1):310.

PMID: 40074873 PMC: 11903978. DOI: 10.1007/s12672-025-02045-w.


Clinical and functional significance of SPATA2 in cancer particularly in LIHC.

Zhou Y, Geng S, Tang R, Yu H, Zhang A, Bai Y Sci Rep. 2025; 15(1):8392.

PMID: 40069269 PMC: 11897323. DOI: 10.1038/s41598-025-91386-1.


PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1/S Progression and Epithelial-Mesenchymal Transition.

Wang L, Kou Z, Zhu J, Zhu X, Gao L, Zhu H Cancer Med. 2025; 14(5):e70749.

PMID: 40062654 PMC: 11891932. DOI: 10.1002/cam4.70749.


References
1.
Samur M . RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One. 2014; 9(9):e106397. PMC: 4152273. DOI: 10.1371/journal.pone.0106397. View

2.
Ricketts C, Hill V, Linehan W . Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One. 2014; 9(1):e85621. PMC: 3893219. DOI: 10.1371/journal.pone.0085621. View

3.
. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636):169-175. PMC: 5651175. DOI: 10.1038/nature20805. View

4.
Reuter J, Spacek D, Snyder M . High-throughput sequencing technologies. Mol Cell. 2015; 58(4):586-97. PMC: 4494749. DOI: 10.1016/j.molcel.2015.05.004. View

5.
Spainhour J, Lim J, Qiu P . GDISC: a web portal for integrative analysis of gene-drug interaction for survival in cancer. Bioinformatics. 2017; 33(9):1426-1428. PMC: 5859986. DOI: 10.1093/bioinformatics/btw830. View